AU2002334889B2 - Nogo receptor-mediated blockade of axonal growth - Google Patents

Nogo receptor-mediated blockade of axonal growth Download PDF

Info

Publication number
AU2002334889B2
AU2002334889B2 AU2002334889A AU2002334889A AU2002334889B2 AU 2002334889 B2 AU2002334889 B2 AU 2002334889B2 AU 2002334889 A AU2002334889 A AU 2002334889A AU 2002334889 A AU2002334889 A AU 2002334889A AU 2002334889 B2 AU2002334889 B2 AU 2002334889B2
Authority
AU
Australia
Prior art keywords
polypeptide
seq
nogo
amino acids
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002334889A
Other languages
English (en)
Other versions
AU2002334889A1 (en
Inventor
Stephen M Strittmatter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of AU2002334889A1 publication Critical patent/AU2002334889A1/en
Application granted granted Critical
Publication of AU2002334889B2 publication Critical patent/AU2002334889B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
AU2002334889A 2001-10-06 2002-10-04 Nogo receptor-mediated blockade of axonal growth Ceased AU2002334889B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/972,599 US7119165B2 (en) 2000-01-12 2001-10-06 Nogo receptor-mediated blockade of axonal growth
US09/972,599 2001-10-06
PCT/US2002/032007 WO2003031462A2 (en) 2001-10-06 2002-10-04 Nogo receptor-mediated blockade of axonal growth

Publications (2)

Publication Number Publication Date
AU2002334889A1 AU2002334889A1 (en) 2003-07-03
AU2002334889B2 true AU2002334889B2 (en) 2006-11-09

Family

ID=25519870

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002334889A Ceased AU2002334889B2 (en) 2001-10-06 2002-10-04 Nogo receptor-mediated blockade of axonal growth

Country Status (6)

Country Link
US (6) US7119165B2 (enExample)
EP (1) EP1451337A4 (enExample)
JP (1) JP4383869B2 (enExample)
AU (1) AU2002334889B2 (enExample)
CA (1) CA2461655A1 (enExample)
WO (1) WO2003031462A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002522016A (ja) * 1998-07-22 2002-07-23 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 神経内分泌特異的タンパク質に類似したタンパク質、およびそれをコードするｃＤＮＡ
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
ES2341608T3 (es) * 2000-10-06 2010-06-23 Yale University Homologos del receptor de nogo.
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
US7745151B2 (en) * 2002-08-02 2010-06-29 Children's Medical Center Corporation Methods of determining binding between Nogo receptor and p75 neurotrophin receptor
ATE469913T1 (de) * 2002-08-10 2010-06-15 Univ Yale Antagonisten des nogo-rezeptors
CN1745094A (zh) * 2002-12-06 2006-03-08 新加坡综合医院有限公司 肽,其抗体,以及它们在中枢神经系统损伤的治疗中的用途
US7842666B2 (en) * 2002-12-20 2010-11-30 Research Foundation Of City University Of New York Inhibitors of myelin-associated glycoprotein (MAG) activity for regulating neural growth and regeneration
PL1606409T3 (pl) 2003-03-19 2011-02-28 Biogen Ma Inc Białko wiążące receptor Nogo
US7541335B2 (en) * 2003-04-04 2009-06-02 University Of Rochester Nogo-receptors and methods of use
CN1832752A (zh) * 2003-04-16 2006-09-13 耶鲁大学 治疗淀粉样蛋白斑相关性病症的nogo－受体拮抗剂
JP2007537985A (ja) * 2003-05-15 2007-12-27 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー 免疫調節ペプチド
EA008253B1 (ru) * 2003-08-07 2007-04-27 Байоджен Айдек Ма Инк. Антагонисты nogo-рецептора
CA2549000A1 (en) * 2003-12-16 2005-06-30 Children's Medical Center Corporation Method for treating neurological disorders
US8912144B2 (en) * 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
US20080045926A1 (en) * 2004-01-30 2008-02-21 Relton Jane K Treatment of Conditions Involving Dopaminergic Neuronal Degeneration Using Nogo Receptor Antagonists
US8039588B2 (en) * 2004-05-21 2011-10-18 The Uab Research Foundation Variable lymphocyte receptors
PT1776136E (pt) * 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
EP1789070B1 (en) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in neuronal function
CN101035803A (zh) * 2004-10-01 2007-09-12 耶鲁大学 Nogo－a多肽片段、变异nogo受体－1多肽、及其应用
US20090010873A1 (en) * 2004-11-29 2009-01-08 Yeda Research And Development Co. Ltd. Methods of Cell Therapy, Neurogenesis and Oligodendrogenesis
EP1904091A4 (en) * 2005-07-07 2009-12-23 Univ Yale COMPOSITIONS AND METHODS FOR SUPPRESSING THE INHIBITION OF AXON GROWTH
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
US20070026463A1 (en) * 2005-07-28 2007-02-01 Wyeth Compositions and methods of mutant Nogo-66 domain proteins
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
CN101248083A (zh) * 2005-08-25 2008-08-20 比奥根艾迪克Ma公司 Nogo受体多肽和多肽片段及其用途
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
EP2526968A3 (en) 2006-01-27 2013-05-22 Biogen Idec MA Inc. Nogo receptor antagonists
WO2007133746A2 (en) * 2006-05-15 2007-11-22 Biogen Idec Ma Inc. Use of nogo receptor-1 (ngr1) antagonists for promoting oligodendrocyte survival
EP2046828A2 (en) * 2006-07-07 2009-04-15 Wyeth Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same
EP2068866A4 (en) 2006-07-24 2010-04-07 Biogen Idec Inc METHODS FOR PROMOTING MYELINIZATION, NEURONAL SURVIVAL AND DIFFERENTIATION OF OLIGODENDROCYTES BY ADMINISTERING SP35 OR TRKA ANTAGONISTS
JP2010502623A (ja) * 2006-08-31 2010-01-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｎｏｇｏレセプターポリペプチドの末梢投与に関する方法
CA2701189C (en) * 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
WO2009061500A1 (en) * 2007-11-08 2009-05-14 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
JP2011505010A (ja) * 2007-11-28 2011-02-17 イェール ユニバーシティー 軸索成長を促進するＮｏｇｏ受容体結合低分子
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
WO2009114197A2 (en) * 2008-03-13 2009-09-17 Yale University Reactivation of axon growth and recovery in chronic spinal cord injury
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
PH12012501070A1 (en) 2009-12-08 2017-08-23 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
AU2013211939C1 (en) 2012-01-27 2018-06-07 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073452A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
EP0396719B1 (en) 1988-11-04 1995-07-05 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
CA1341050C (en) 1988-11-04 2000-07-11 Martin E. Schwab Neurite growth regulatory factors
US5858708A (en) 1996-08-12 1999-01-12 Bandman; Olga Polynucleotides encoding two novel human neuroendocrine-specific proteins
US7368531B2 (en) * 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
US6962797B2 (en) * 1998-04-15 2005-11-08 Genentech, Inc. Nucleic acids encoding PRO615
CA2331154A1 (en) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. Polypeptides having sequence identity with acid labile subunit of insulin-like growth factor
JP2002522016A (ja) 1998-07-22 2002-07-23 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 神経内分泌特異的タンパク質に類似したタンパク質、およびそれをコードするｃＤＮＡ
SK287323B6 (sk) 1998-11-06 2010-07-07 University Of Z�Rich Nogo proteín, jeho purifikovaný fragment, chimérny proteín a purifikovaná molekula s jeho obsahom, izolovaná nukleová kyselina, vektor s jej obsahom, rekombinantná bunka, spôsob produkcie rekombinantného proteínu a jeho použitie
US6152155A (en) 1998-11-30 2000-11-28 Milligan; Lon Filter cleaning device
KR100529270B1 (ko) 1998-12-01 2005-11-21 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제
IL143031A0 (en) 1998-12-22 2002-04-21 Genentech Inc Methods and compositions for inhibiting neoplastic cell growth
US7041474B2 (en) 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
KR20010103046A (ko) 1999-03-08 2001-11-17 제넨테크, 인크. 면역 관련 질환 치료용 조성물 및 치료 방법
EP1263948A2 (en) 1999-03-08 2002-12-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004507202A (ja) 1999-03-31 2004-03-11 キュラジェン　コーポレイション ポリペプチドをコードするオープンリーディングフレームを含む核酸；「ｏｒｆｘ」
AU3632600A (en) 1999-05-14 2000-12-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
EP1268506A4 (en) 1999-07-30 2004-07-28 Millennium Pharm Inc SECRET PROTEINS AND THEIR USE
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
HUP0203863A3 (en) 2000-01-12 2008-03-28 Univ Yale Nogo receptor-mediated blockade of axonal growth
ES2341608T3 (es) * 2000-10-06 2010-06-23 Yale University Homologos del receptor de nogo.
EP1423427A2 (en) 2001-08-27 2004-06-02 Novartis AG Nogo receptor homologues and their use
WO2003035687A1 (en) 2001-10-22 2003-05-01 Novartis Ag Nogo receptor homologues and their use
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
US20030113325A1 (en) * 2001-12-03 2003-06-19 Zhigang He Reducing myelin-mediated inhibition of axon regeneration
EP1354892A1 (en) 2002-04-19 2003-10-22 Centre National De La Recherche Scientifique (Cnrs) Peptides capable of inducing attraction of the axonal growth and their use for treating neurodegenerative diseases
US7745151B2 (en) * 2002-08-02 2010-06-29 Children's Medical Center Corporation Methods of determining binding between Nogo receptor and p75 neurotrophin receptor
ATE469913T1 (de) 2002-08-10 2010-06-15 Univ Yale Antagonisten des nogo-rezeptors
CN1832752A (zh) * 2003-04-16 2006-09-13 耶鲁大学 治疗淀粉样蛋白斑相关性病症的nogo－受体拮抗剂
JP2007501612A (ja) 2003-08-07 2007-02-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｎｏｇｏ受容体アンタゴニスト
EA008253B1 (ru) * 2003-08-07 2007-04-27 Байоджен Айдек Ма Инк. Антагонисты nogo-рецептора
US20080045926A1 (en) * 2004-01-30 2008-02-21 Relton Jane K Treatment of Conditions Involving Dopaminergic Neuronal Degeneration Using Nogo Receptor Antagonists
WO2009114197A2 (en) 2008-03-13 2009-09-17 Yale University Reactivation of axon growth and recovery in chronic spinal cord injury

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073452A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FOURNIER A et al Nature (2001) 409: 341-346 *

Also Published As

Publication number Publication date
JP4383869B2 (ja) 2009-12-16
EP1451337A4 (en) 2005-08-17
US20020077295A1 (en) 2002-06-20
US20140178392A1 (en) 2014-06-26
CA2461655A1 (en) 2003-04-17
US20170174763A1 (en) 2017-06-22
WO2003031462A2 (en) 2003-04-17
US20080219984A1 (en) 2008-09-11
EP1451337A2 (en) 2004-09-01
US8394929B2 (en) 2013-03-12
US20130171157A1 (en) 2013-07-04
US20100278831A1 (en) 2010-11-04
US7119165B2 (en) 2006-10-10
WO2003031462A3 (en) 2003-12-04
JP2005508165A (ja) 2005-03-31

Similar Documents

Publication Publication Date Title
US8394929B2 (en) Nogo receptor-mediated blockade of axonal growth
EP1248803B1 (en) Nogo receptor-mediated blockade of axonal growth
AU2002334889A1 (en) Nogo receptor-mediated blockade of axonal growth
US20090136970A1 (en) Nogo receptor homologues and their use
US20080118951A1 (en) Nogo receptor homologues and their use
KR100856360B1 (ko) 절단형 ｄａｎｃｅ, ｄａｎｃｅ 복합체, 및 이들을사용하는 방법
AU2006200819B2 (en) Nogo Receptor-Mediated Blockade of Axonal Growth
KR20060136471A (ko) 절단형 ｄａｎｃｅ, ｄａｎｃｅ 복합체, 및 이들을사용하는 방법
ZA200205403B (en) Nogo receptor-mediated blockade of axonal growth.
NZ547791A (en) Nogo receptor-mediated blockade of axonal growth
US20030087387A1 (en) Human toll homologues
EP1932854A1 (en) Lysosomal associated membrane protein (LAMP) - like polypeptide, ligands to the same, and use of the same in the frame of detection and purification of human plasmacytoid dendritic cells

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired